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Abstract
With the improvements in short and long term graft and patient survival after renal transplantation
over the last two decades Health- R e l at e d  Qu a l i t y  o f  L i f e  ( H R QL ) i s b e c om i ng  a n  i m po r t an t
additional outcome parameter. Global and disease specific instruments are available to evaluate
objective and subjective QOL. Among the most popular global tools is the SF-36, examples of
disease specific instruments are the Kidney Transplant Questionnaire (KTQ), the Kidney Disease
Questionnaire (KDQ) and the Kidney Disease-Quality of Life (KDQOL). It is generally accepted
that HRQL improves dramatically after successful renal transplantation compared to patients
maintained on dialysis treatment but listed for a transplant. It is less clear however which
immunosuppressive regimen confers the best QOL. Only few studies compared the different
regimens in terms of QOL outcomes. Although limited in number, these studies seem to favour
non-cyclosporine based protocols. The main differences that could be observed between patients
on cyclosporine versus tacrolimus or sirolimus therapy concern the domains of appearance and
fatigue. This may be explained by two common adverse effects occurring under cyclosporine
therapy, gingival hyperplasia and hair growth. Another more frequently occurring side effect under
calcineurin inhibitor therapy is tremor, which may favour CNI free protocols. This hypothesis,
however, has not been formally evaluated in a randomised trial using HRQL measurements.
In summary HRQL is becoming more of an issue after renal transplantation. Whether a specific
immunosuppressive protocol is superior to others in terms of HRQL remains to be determined.
Introduction
Health-related quality of life (HRQL) contains multiple
aspects of health related issues from the patients' perspec-
tive including physical, psychological, and social func-
tioning and overall well-being [1-3]. Numerous clinical
trials have established the importance of HRQL in various
diseases, and it is increasingly popular to evaluate disease-
specific and generic HRQL in clinical trials as a measure of
patients' subjective state of health.
HRQL is also increasingly recognised as an important
measure of outcome following solid organ transplanta-
tion. Along with significant quantitative improvements in
patient and graft survival, HRQL has been appreciated as
another valid outcome measurement.
HRQL investigations take a broad view on subjective
health issues and consider health as a puzzle of singular
domains of well-being. The pieces of this puzzle are psy-
chological and social aspects of well-being in addition to
physical and mental health. Some of these pieces are eval-
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uated on either a subjective or an objective basis, some
domains by both dimensions [3].
Kidney transplantation is the treatment of choice for end
stage renal disease (ESRD). Advances in renal transplant
procedures and immunosuppressive therapies have
increased dramatically over the last decades, one year allo-
graft survival rates are currently over 90 % [4]. The major
goal of transplantation is the achievement of maximal
quality and quantity of life while minimising the effects of
disease and in renal transplantation also the costs of care.
The units in which these socio-biological terms are
reported depend on the condition that is being evaluated.
Examples of these measures are quality-adjusted life years
gained, disease-free life years gained, or healthy-year
equivalents per unit cost of care. In renal transplantation
the costs of care are not only limited to the transplant pro-
cedure but also to the evolving costs to treat adverse
events, some of them caused by the immunosuppressive
therapy.
Since the first successful kidney transplantation in the
early 1950s, immunosuppressive therapies improved con-
siderably, the most revolutionary development being the
introduction of cyclosporine in the early 1980s. The intro-
duction of new immunosuppressive agents has further
increased the therapeutic options for immunosuppressive
combination therapies in transplanted patients.
In parallel to better patient care and new immunosuppres-
sive regimens the median survival of renal allografts
improved continuously [5]. Hand in hand with these
achievements, greater attention has been given to long-
term QOL. However, so far HRQL was evaluated only in a
limited number of clinical trials as subjective state of
health [6-15]. It is generally accepted however, that
patients with a functioning renal allograft have an
improved HRQL as compared to patients on dialysis
[14,16].
Measurement tools for HRQL after kidney 
transplantation
To evaluate the impact of a specific disease on HRQL, spe-
cific evaluation tools have to be utilised. These tools are
sensitive enough to determine longitudinal changes of a
disease but they are not appropriate to compare different
diseases.
Disease-specific tools in HRQL evaluation after renal
transplantation include the Kidney Transplant Question-
naire (KTQ) [17], the Kidney Disease-Quality of Life
(KDQOL) [18] and the End Stage Renal Disease Symptom
Checklist Transplantation Module (ESRDSC-TM) [19].
The same authors that invented the KTQ previously devel-
oped a dialysis specific HRQL questionnaire which is
known as the Kidney Disease Questionnaire (KDQ) [17].
The KTQ as the first cited examples contains 26 questions
in five domains (physical symptoms, depression, fatigue,
relationship with others, frustration) each of which can be
scored on a scale from 1 to 7, where the lowest score rep-
resents the lowest QOL. For the final analysis all points
are summed up, thus the maximum score is 182 and the
minimum 26 points. As others, these questionnaire need
to be evaluated in the native language of the patient. A
recent example of a KTQ evaluation study was performed
by colleagues from Oviedo, Spain [20].
The KDQOL was initially developed for patients with
chronic renal disease and dialysis patients. However,
recent papers used this tool for the evaluation of trans-
plant patients as well in order to compare them to patients
on hemo- and peritonealdialysis [21]. The original
KDQOL covers eleven dimensions with a different
number of items. The dimension symptoms/problems
include 34 items, effects of kidney disease on daily life 20
items, burden of kidney disease 4 items, cognitive func-
tion 6 items, work status 4 items, sexual functions 4 items,
quality of social interaction 4 items, sleep 9 items, social
support 4 items and patient satisfaction 2 items. In case of
dialysis patients the domains dialysis staff encouragement
with 6 items completes the list. The response options is a
Likert scale whereas higher scores denote better QOL.
The ESRDSC-TM was specifically developed to evaluate
the effects of immunosuppressant medication on QOL.
The distributed questions are scored on a five-point Likert
scale, again where higher scores represent better QOL.
The authors tested over 400 transplant patients and eval-
uated the test-retest correlation in a subset of 88 patients
at an interval of one year and found adequate validity.
As in the above study, global indices are also used in renal
transplant recipients. These tests summarize the global
assessment of functioning and well-being into a single
index value. In order to define this value the patient is
asked to indicate her/his preference for a variety of speci-
fied health states.
Until now no single method has been shown to be ideal
for measure HRQL under all circumstances. By comparing
HRQL results from studies using different measuring
tools, it is possible to get similar numerical results but a
discrepancy in meaning. It has been shown that very dif-
ferent HRQL results can be obtained in the same popula-
tion if different tools are used [22].Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/2
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There are also generic tools used to determine the impact
of any of a number of diseases in HRQL. Generic tools are
useful for comparisons among groups and studies and for
evaluating the impact of different diseases on QOL. These
tools are used in HRQL research and include tests such as
the Sickness Impact Profile (SIP), the 36-item short-form
of Medical Outcomes Survey (SF-36), and the Notting-
ham Health Profile (NHP).
With more than 2000 publications, the SF-36 is one of the
most widely used quality of life instruments worldwide
[23,24]. The SF-36 questionnaire is a self administered
survey and contains 36 items that take a few minutes to
complete. It includes one multi-item scale that assesses
eight health domains: 1) limitations in physical activities
because of health problems; 2) limitations in social activ-
ities because of physical or emotional problems; 3) limi-
tations in usual role activities because of physical health
problems; 4) bodily pain; 5) general mental health; 6)
limitations in usual role activities because of emotional
problems; 7) vitality; 8) general health perceptions.
Six dimensions are formed of Likert- or summative scales
with three to six answer categories and verbal anchors for
each answer category. Two tests are designed as Guttman-
or cumulative scales with four dichotomous yes/no items
for each category. Five of these dimensions are similar to
the Nottingham health profile (NHP), but items in the SF-
36 questionnaire are claimed to detect positive as well as
negative states of health. For each dimension, item scores
are coded, summed and transformed on a scale between 0
(worst) and 100 (best).
Studies evaluating HRQL after renal 
transplantation
The first to study the long-term quality of life after kidney
and simultaneous kidney and pancreas transplantation
were colleagues from Minnesota. In 1998 Matas and cow-
orkers described the QOL assessed by using the SF-36
form [25]. The authors managed to have 446 patients
evaluated once, 632 twice and 53 three times. The patients
were between one and ten years after transplantation. The
SF-36 scores did not change significantly over the years
after transplantation and were consistently lower com-
pared to the normal US population. Interestingly, diabetic
and non-diabetic subjects scored similar on the mental
health scales whereas non-diabetic patients scored better
on physical functioning and on general health.
The same authors recently published a longitudinal rela-
tionship between adverse effects particular of immuno-
suppressive drugs in renal transplant recipients and QOL
[9]. In this huge study 4247 self-selected patients were
enrolled and assessed by a QOL questionnaire. The
authors conducted a multivariate analysis which showed
that emotional problems, reduced sexual interest and
headache were the main factors that negatively influenced
QOL in these patients. Preliminary data from this self-
reported health information program entitled the "Trans-
plant Learning Center" were published by Hricik and col-
leagues [10]. The initial results obtained in 3676 patients
were similar to those published in the final report one
year later on 4247 patients.
A recent paper, also from the University of Minnesota but
from different authors, evaluated the impact of transplan-
tation on QOL in diabetic patients with ESRD [11]. Spe-
cifically, the authors addressed the interesting question
whether simultaneous kidney/pancreas transplantation
(KPT) confers a better QOL than kidney transplantation
alone with subcutaneous insulin therapy. Most QOL read-
ings improved after transplantation in both groups. After
adjustment for co-morbidities, the authors found higher
SF-36 scores in KPT in the domains of physical function-
ing, bodily pain, general health and the physical compo-
nent. The better physical scores could be attributed to the
perceived benefits of reduced secondary diabetes compli-
cations, the higher mental scores remained unexplained.
Johnson and colleagues published the first study that eval-
uated changes in QOL in the first year after renal trans-
plantation split by gender and race [13]. The authors used
three questionnaires to assess HRQL, the Sickness Impact
Profile, Ferrans and Powers' Quality of life index, and the
adult self image scales. African-American patients
observed less QOL improvement compared to Caucasian
patients, and women scored consistently lower than men.
This study demonstrates nicely the although all partici-
pants improved their QOL, considerable racial and gender
differences exist and these differences may affect care
requirements.
Very recently, Franke et al. evaluated the HRQL in patients
with end stage renal failure [26]. The trial explored the dif-
ferences in HRQL among patients on the waiting list for
kidney transplantation while maintained on hemodialy-
sis and recipients of renal transplants. The outcome was
measured with generic (SF-36) and disease specific tools
(End Stage Renal Disease Symptom Checklist-Transplan-
tation Module). In that trial the group of 80 dialysis
patients on the transplant waiting list experienced a
decreased satisfaction with social support, while the 222
patients after successful renal transplantation exhibited an
increase of social support. Similarly, psychological dis-
tress was higher among patients on maintenance haemo-
dialysis compared to the transplanted subjects.
A similar study in design by Jofre and coworkers found
similar improvements in 88 out of 93 patients after suc-
cessful renal transplantation [14]. The authors used theHealth and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/2
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Karnovsky Scale and the Sickness Impact Profile as evalu-
ation tools. It is of note that although each transplant
patient served as her/his own control and exhibited
improved scores after transplantation, mainly the male
patients reported a marked improvement in global scores,
similar to what has been demonstrated by Johnson in the
same year. As anticipated older patients and subjects with
more comorbidities revealed less improvement compared
to younger and fitter subjects.
In a randomised open-label trial in Europe, Australia and
Canada Oberbauer and coworkers investigated the HRQL
outcomes in patients after kidney transplantation [6]. In
that trial 430 kidney transplant patients were randomly
assigned three months after transplantation to continue
cyclosporine and sirolimus therapy or to have
cyclosporine withdrawn over a period of four weeks. The
HRQL was measured at randomisation, and at one and
two years after transplantation using the disease-specific
KTQ tool and the generic SF-36 tool. Randomisation
worked fine and no differences in baseline HRQL could
be observed. In the two years follow-up investigation, the
authors found a statistically significant improvement in
two domains of the KTQ, fatigue and appearance in the
cyclosporine free group. Furthermore, vitality scores in the
SF-36 questionnaire were higher in the cyclosporine free –
sirolimus group at two years compared to baseline values,
but decreased in the combination group. It is of interest
that the SF-36 vitality score of 64 in the sirolimus-steroid
group at two years is higher than the mean SF-36 vitality
score in the general US population which is reported to
average 61. The other SF-36 scores were not different
among groups at two years and generally lower than those
reported for the general US population. These findings are
consistent with those reported elsewhere for renal trans-
plant recipients [8]. Shield reported that one year after
transplantation, the study population score in vitality was
in the 50th percentile of an age matched general US popu-
lation.
Reimer et al compared the HRQL among 63 cyclosporine
and an equal number of tacrolimus treated renal trans-
plant recipients between 1997 and 1999 [7]. HRQL was
assessed using the SF-36 and a disease-specific QOL-
instrument, the End-Stage Renal Disease Symptom
Checklist – Transplantation Module (ESDR-SCL). The
measurements were performed at transplantation and one
year thereafter, time after transplantation and the type of
immunosuppression were included into the regression
model as independent variables. Patients with tacrolimus-
based immunosuppression reported significantly better
global and disease specific HRQL than those receiving
cyclosporine microemulsion.
Discussion
HRQL is becoming more of an issue in terms of outcome
measurements after renal transplantation. Advances in
immunosuppressive therapy improved graft and patient
survival, but it remains unknown whether this objective
success projected also in subjective patients appreciation
and well-feeling. Kidney transplant recipients life with
varying degrees of disease specific physical and psychical
impairments, some of them attributed to immunosup-
pressant adverse effects. In few clinical trials of renal trans-
plantation medium-term HRQL outcomes of patients on
different immunosuppressive regimen were investigated
[6-8].
Among the first authors that evaluated HRQL in renal
transplant patients and compared different immunosup-
pressive regiments on that outcome were Shield and col-
leagues. Similar to subsequent studies by Oberbauer et al.
and Reimer et al. the authors found an improvement of
HRQL after transplantation. Rejection episodes were asso-
ciated with less improvement of HRQL. Furthermore,
HRQL was statistically significant different by treatment.
Tacrolimus treatment was associated with better appear-
ance in the Bergner Physical Appearance Scale, which was
designed to measure cosmetic side effects of medical ther-
apy such as gingival hyperplasia and hirsutism.
In the study by Reimer and coworkers, which investigated
QOL in two groups of 63 patients receiving cyclosporine
or tacrolimus respectively similar results were obtained.
Patients on tacrolimus immunosuppression exhibited sta-
tistically higher scores in two domains of the global test
(SF-36) as well as in three subgroups of the disease spe-
cific questionnaire. The two domains of the global test
with higher scores were "Physical Functioning" and "Gen-
eral Health", the three areas of the specific test were tac-
rolimus patients scored better were "Limited Physical
Capacity", "Cardial and Renal Dysfunction" and
"Increased Growth of Gum and Hair".
These two studies suggest that patients experience a better
physical state and appearance on tacrolimus than on
cyclosporine. Although the study by Oberbauer and col-
leagues did not compare tacrolimus to cyclosporine but
rather evaluated the impact of early cyclosporine elimina-
tion form a combination regimen with sirolimus, similar
results were obtained at one and two years after transplan-
tation. Statistically significant treatment by assessment
time interactions were observed for SF-36 vitality scores in
patients after cyclosporine withdrawal. In the disease spe-
cific evaluation by the KTQ (kidney transplant question-
naire), patients off cyclosporine scored higher in the
appearance score and felt less fatigue than those on a com-
bination of cyclosporine and low dose sirolimus.Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/2
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Besides the evaluation of the effects of different immuno-
suppressive protocols on HRQL after transplantation, it is
feasible to discuss the potential importance of HRQL eval-
uations before transplantation and the probable implica-
tion of obtained scores on patient selection for
transplantation. As discussed in context with the study by
Jofre and colleagues, older and multimorbid patients
gained less improvement after transplantation than
younger subjects. It is also well known in these older sub-
jects that the time from transplantation to the point where
subjects have an advantage from the transplant procedure
in terms of survival benefits compared to wait listed but
not transplanted matched subjects is almost twice as long
as in younger subjects [27]. These two arguments would
suggest that renal transplantation is not the preferable
renal replacement therapy in elderly patients with end
stage disease. This hypothesis however is easy to reject.
Firstly although it takes roughly one year in patients
between 60 and 70 years of age until the likelihood of sur-
vival is higher than for matched wait listed dialysis
patients, there is no discussion that overall survival is
higher than on dialysis. Secondly, renal transplantation is
more cost effective than dialysis treatment also in elderly
patients if offered within a timely period after develop-
ment of end stage renal failure [28]. Therefore the evalua-
tion and results of HRQL obtained before transplantation
may not be used as criterion for the selection of patients
for the transplant waiting list.
The scores of a pre-transplant evaluation of HRQL may
however be useful for the detection of non-compliant
patients. A regular intake of the prescribed immunosup-
pressive drugs is key to prevent graft rejection in these sub-
jects and a considerable number of late acute rejections
are cause by incompliant patients that stopped their
immunosuppression [29]. If such patients at risk could be
identified in advance for example by HRQL question-
naires, a strategy could be adopted to improve compli-
ance. Such strategies would include more support from all
members of a transplant team and also shorter follow-up
intervals as outpatient to check the immunosuppressive
trough levels more frequently than in compliant patients.
So far however, not data exist on the feasibility of this con-
cept. Future studies of HRQL in renal transplantation
however should evaluate whether medication compliance
of patients can be predicted before transplantation.
What is needed in renal transplantation is a questionnaire
administered before transplantation that has predictive
power for the QOL of these patients in the post-transplant
period. Patients may give their preferences in terms of
QOL and the results of this survey may be included into
the doctors algorithm of choice for a specific post-trans-
plant care and drug regimen. This sounds logical but was
impossible in the past because only a very limited arma-
mentarium of immunosuppressive drugs were available.
In the last years however several new immunosuppressive
drugs were investigated in renal transplant recipients and
thus a stronger incorporation of patients preferences on
drug selection might be possible.
Conclusions
In conclusion, although clinical trials evaluating the
HRQL in patients after renal transplantation are relatively
scarce, the few published papers yielded rather similar
results. In general HRQL improved after successful kidney
transplantation compared to dialysis, this effect was more
pronounced in male than in female patients. Although
not a big surprise, these studies first document that renal
transplantation is not only the cheaper renal replacement
therapy in the long term and associated with less mortality
but also provides a better quality of patients' life. Further-
more, these trials showed that physical activity, energy
and appearance are important domains that are influ-
enced by the mandatory immunosuppressive regimen.
Thus, if equal clinical effectiveness of some commonly
used immunosuppressive regimens is assumed, the physi-
cians' algorithm of identifying the optimal regimen for a
specific patient should also include the patients' prefer-
ences for individual important QOL domains.
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